<DOC>
	<DOCNO>NCT00351663</DOCNO>
	<brief_summary>The purpose study evaluate efficacy 3 different dose regimen enoxaparin achieve adequate antithrombotic aFXa level critically ill patient . The relationship appearance DVT antithrombotic aFXa level also assess risk factor associate inadequate aFXa level standard enoxaparin dosage search .</brief_summary>
	<brief_title>The Effect Vasopressors Anti Xa Response Enoxaparin Critically Ill Patients</brief_title>
	<detailed_description>Critically ill patient increase risk venous thrombosis embolism DVT . Low molecular weigh heparin enoxaparin ( clexane ) favorable pharmacokinetic/ pharmacodynamic profile , equivalent improve efficacy ( e.g . post trauma orthopedic surgery patient ) few bleed complication low-dose unfractionated heparin . These medication currently recommend DVT prophylaxis critically ill patient usually administer subcutaneously ( SQ ) . The antithrombotic activity LMWHs correlate peak aFXa level . However , appropriate dose dose interval enoxaparin DVT prophylaxis critically ill surgical patient establish particular remains unknown patient severe peripheral edema ans/or decrease peripheral circulation due therapy vasopressor . Several study recently demonstrate questionable efficacy standard daily enoxaparin dose critically ill patient DVT prophylaxis . The current study prospective , randomize , cohort study , conduct Shaare Zedek Medical Center period 1 year ( 100 patient ) . All critically ill patient age ≥18 year predict requirement mechanical ventilation &gt; 3 day include . Data collection perform anonymously include patient demographic admission detail , duplex monitoring DVT daily record APACHE II score , renal function , coagulation profile overall dose vasopressor . Patients randomize receive enoxaparin accordance three DVT prophylaxis protocols- IV weight , SQ weight SQ 40mg x1/day ( standard ) . Blood sample evaluation aFXa draw twice daily peak trough activity period 5 day . No change make standard therapy . Patient outcomes occurrence adverse event record . The principle outcome variable achievement target peak trough level aFXa 5 day study period .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vasoconstrictor Agents</mesh_term>
	<criteria>All critically ill patient , age ≥18 year , predict requirement mechanical ventilation 3 day venous thromboembolic prophylaxis indicate . 1 . Patients require full anticoagulation 2 . Administration unfractionated heparin 8hrs precede study entry 3 . Existing contraindication prophylactic dose enoxaparin . 4 . Platelets &lt; 75,000 5 . Significant renal failure ( creatinine clearance &lt; 30 ml/min/m2 ) [ 39 ] 6 . BMI &gt; 30 7 . INR &gt; 1.7 8 . Any condition preclude treatment opinion primary physician 9 . Patient /surrogate refusal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Critical Illness</keyword>
	<keyword>Blood Coagulation</keyword>
	<keyword>Factor Xa</keyword>
</DOC>